Armani Group Eyes Strategic Stake Sale to Luxury Giants 
Shell Q1 Profit Surges to Two-Year High as Dividend Rises Despite War-Driven Debt Pressure 
China Banks Halt New Loans to Sanctioned Refineries Amid U.S.-Iran Oil Crackdown 
Aker BP Q1 Profit Jumps on Higher Oil Prices and Asset Reversal 
Continental AG Shares Jump After Q1 Profit Beats Expectations 
Lufthansa Q1 Loss Narrows as Strong Summer Travel Demand Boosts Outlook 
CoreWeave Q1 2026 Revenue Surges as AI Infrastructure Demand Grows 
Hua Hong Semiconductor Stock Surges to Multi-Year High Amid AI Boom 
AWS Data Center Overheating Disrupts Cloud Services in Northern Virginia 
BMW Keeps 2026 Outlook Despite 25% Profit Drop Amid Tariff Pressure 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
Coinbase Q1 2026 Earnings Miss Sends COIN Stock Lower Amid Crypto Market Slump 
Judge Delays SEC Settlement With Elon Musk Over Twitter Stock Disclosure Case 
Morgan Stanley Bets on Optical Component Stocks in Greater China Tech Sector 
Dell Stock Hits Record High After Trump Endorsement, AI Server Demand Fuels Rally 
Nike Tariff Refund Lawsuit Sparks Consumer Backlash Over Price Increases 
Orsted Q1 EBITDA Beats Expectations Despite U.S. Impairments 
GSK just fired Moncef Slaoui from his post as Galvani Bioelectronics board chairman this week. The executive also served as the chief scientist for the U.S. government’s Operation Warp Speed, a coronavirus vaccine development group under Donald Trump’s administration.
CNBC reported that GlaxoSmithKline terminated Slaoui due to sexual harassment claims that were raised by a woman who was not named. His dismissal was announced by GSK on March 24.
The alleged offenses that led to Slaoui’s dismissal
Slaoui was a scientist and board chair at Galvani Bioelectronics, where GSK is a major shareholder. This is why it was GlaxoSmithKline that made the decision to get rid of him.
Moreover, it was revealed that in February, GSK received a letter that described Slaoui’s sexual harassment offenses and other misconducts committed toward the company’s employees. Based on the allegations, Dr. Slaoui’s inappropriate conduct happened several years ago when he was still working directly for GlaxoSmithKline.
After the concerns have been raised over the former board chairman’s behavior, GSK acted swiftly and axed the erring executive. His dismissal is effective immediately. At any rate, Slaoui lost his job 10 months after Trump appointed him to manage the country’s effort to develop COVID-19 vaccines.
“Dr. Slaoui's behaviors are wholly unacceptable,” GSK stated via a press release that was posted on March 24. “They represent an abuse of his leadership position, violate company policies, and are contrary to the strong values that define GSK's culture.”
It was added that everyone at GSK is expected to behave in accordance with the company’s values, especially its leaders. The firm then stressed that sexual harassment and other abuse of leadership are not tolerated and strictly prohibited.
About Moncef Slaoui
The fired Moncef Slaoui is 61 years old now and has been with GSK for 30 years. His wife, Kristen Slaoui, was a former GSK’s vice president and head of business development in the past.
When he was assigned as the chief advisor of Operation Warp Speed, he was a board member at Moderna pharmaceuticals. Due to criticisms for his connection to Moderna, while being an official at OWS, he resigned from the board of Moderna and sold his shares. However, Slaoui refused to give up his shares in GSK and said that those are his “retirement plan.”
